Overdiagnosis in lung cancer screening: Estimates from the German Lung Cancer Screening Intervention Trial
Open Access
- 15 September 2020
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 148 (5) , 1097-1105
Abstract
Overdiagnosis is a major potential harm of lung cancer screening; knowing its potential magnitude helps to optimize screening eligibility criteria. The German Lung Screening Intervention Trial (“LUSI”) is a randomized trial among 4052 long‐term smokers (2622 men), 50.3 to 71.9 years of age from the general population around Heidelberg, Germany, comparing five annual rounds of low‐dose computed tomography (n = 2029) with a control arm without intervention (n = 2023). After a median follow‐up of 9.77 years postrandomization and 5.73 years since last screening, 74 participants were diagnosed with lung cancer in the control arm and 90 in the screening arm: 69 during the active screening period; of which 63 screen‐detected and 6 interval cancers. The excess cumulative incidence in the screening arm (N = 16) represented 25.4% (95% confidence interval: −11.3, 64.3] of screen‐detected cancer cases (N = 63). Analyzed by histologic subtype, excess incidence in the screening arm appeared largely driven by adenocarcinomas. Statistical modeling yielded an estimated mean preclinical sojourn time (MPST) of 5.38 (4.76, 5.88) years and a screen‐test sensitivity of 81.6 (74.4%, 88.8%) for lung cancer overall, all histologic subtypes combined. Based on modeling, we further estimated that about 48% (47.5% [43.2%, 50.7%]) of screen‐detected tumors have a lead time ≥4 years, whereas about 33% (32.8% [28.4%, 36.1%]) have a lead time ≥6 years, 23% (22.6% [18.6%, 25.7%]) ≥8 years, 16% (15.6% [12.2%, 18.3%]) ≥10 years and 11% (10.7% [8.0%, 13.0%]) ≥12 years. The high proportions of tumors with relatively long lead times suggest a major risk of overdiagnosis for individuals with comparatively short remaining life expectancies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (BE 2486/2‐1, BE 2486/2‐2)
This publication has 27 references indexed in Scilit:
- Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO TrialsCancer Epidemiology, Biomarkers & Prevention, 2015
- Overdiagnosis in Low-Dose Computed Tomography Screening for Lung CancerJAMA Internal Medicine, 2014
- The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histologyCancer, 2013
- Chapter 7: Description of MISCAN‐Lung, the Erasmus MC Lung Cancer Microsimulation Model for Evaluating Cancer Control InterventionsRisk Analysis, 2012
- Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening roundJournal of Cancer Research and Clinical Oncology, 2012
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Tobacco smoking as a risk factor of bronchioloalveolar carcinoma of the lung: pooled analysis of seven case–control studies in the International Lung Cancer Consortium (ILCCO)Cancer Causes & Control, 2010
- Overdiagnosis in CancerJNCI: Journal of the National Cancer Institute, 2010
- Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screeningBritish Journal of Cancer, 2009
- The Effect of Smoking on Years of Healthy Life (YHL) Lost among Middle‐Aged and Older AmericansHealth Services Research, 2004